Executive Summary

Between January 2025 and March 2026, valvular heart disease crossed a strategic threshold.

Not a device revolution. Not a single headline trial. Something more consequential: a fundamental shift from procedural validation to lifetime architectural planning.

For two decades, the ...

“Two patients. Both have severe aortic stenosis. Both feel fine. One is told to wait. The other is offered early intervention. Which one wins? And more importantly — how do we decide?”

That’s the paradox at the heart of asymptomatic severe aortic stenosis — a condition that continues to challen...